%0 Report
%A Rodriguez-Pardo, Dolors
%A Del -Toro, Maria Dolores
%A Guio-Carrion, Laura
%A Escudero-Sanchez, Rosa
%A Fernandez-Sampedro, Marta
%A Garcia-Viejo, Miguel Angel
%A Velasco-Arribas, Maria
%A Soldevila-Boixader, Laura
%A Femenias, Magdalena
%A Iribarren, Jose Antonio
%A Pulido-Garcia, Maria Del Carmen
%A Navarro, Maria Dolores
%A Lung, Mayli
%A Corona, Pablo S
%A Almirante, Benito
%A Pigrau, Carles
%T Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial.
%D 2021
%U http://hdl.handle.net/10668/17592
%X To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. early-PJI after HHA. Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33-3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15-7.10]). Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47.
%K Asymptomatic bacteriuria
%K Early-periprosthetic joint infection
%K Fosfomycin-trometamol
%K Hip hemiarthroplasty
%~